SECURING THE Pb-212 SUPPLY CHAIN
IsoMedica’s Mines to Medicines project is addressing global supply chain challenges that are compromising the expansion of Pb-212 production for targeted alpha therapy for hard to treats cancers. Renowned for it’s favoured in-body chemistry, Pb-212 includes a quick exit from the body.
Transforming Waste into Life-Saving Medical Isotopes
We are establishing a vertical supply chain capability, leveraging existing expertise and contacts upstream into the resources and energy sectors, to source waste and underutilised materials rich in Radium and Thorium isotopes that are key inputs to the production of Pb-212 radiopharmaceuticals.
entX has also signed a collaboration agreement with Tellus Holdings, Australia’s only commercial repository for many of these sources. The Mines to Medicines project is funding through the Cooperative Research Centre Projects and Economic Recovery programs, bring together academic and industry partners that will drive the establishment of the entX Advanced Radioisotope Production Facility (ARPF) in South Australia.
The ARPF will be a licensed facility producing commercial quantities of medical grade Thorium precursor for supply to manufacturers of Pb-212 radiopharmaceuticals by the end of 2025.
OTher Projects